295 related articles for article (PubMed ID: 32304700)
21. Mammalian Surface Display Screening of Diverse Cystine-Dense Peptide Libraries for Difficult-to-Drug Targets.
Crook ZR; Sevilla GP; Mhyre AJ; Olson JM
Methods Mol Biol; 2020; 2070():363-396. PubMed ID: 31625107
[TBL] [Abstract][Full Text] [Related]
22. BBB-targeting, protein-based nanomedicines for drug and nucleic acid delivery to the CNS.
Peluffo H; Unzueta U; Negro-Demontel ML; Xu Z; Váquez E; Ferrer-Miralles N; Villaverde A
Biotechnol Adv; 2015; 33(2):277-87. PubMed ID: 25698504
[TBL] [Abstract][Full Text] [Related]
23. [Development of Noninvasive Drug Delivery Systems to the Brain for the Treatment of Brain/Central Nervous System Diseases].
Kanazawa T
Yakugaku Zasshi; 2018; 138(4):443-450. PubMed ID: 29607986
[TBL] [Abstract][Full Text] [Related]
24. Nanomaterial-mediated CNS delivery of diagnostic and therapeutic agents.
Biddlestone-Thorpe L; Marchi N; Guo K; Ghosh C; Janigro D; Valerie K; Yang H
Adv Drug Deliv Rev; 2012 May; 64(7):605-13. PubMed ID: 22178615
[TBL] [Abstract][Full Text] [Related]
25. From naturally-occurring neurotoxic agents to CNS shuttles for drug delivery.
Soddu E; Rassu G; Giunchedi P; Sarmento B; Gavini E
Eur J Pharm Sci; 2015 Jul; 74():63-76. PubMed ID: 25892455
[TBL] [Abstract][Full Text] [Related]
26. Smart Strategies for Therapeutic Agent Delivery into Brain across the Blood-Brain Barrier Using Receptor-Mediated Transcytosis.
Tashima T
Chem Pharm Bull (Tokyo); 2020; 68(4):316-325. PubMed ID: 32238649
[TBL] [Abstract][Full Text] [Related]
27. Intranasal drug delivery to the central nervous system: present status and future outlook.
Tayebati SK; Nwankwo IE; Amenta F
Curr Pharm Des; 2013; 19(3):510-26. PubMed ID: 23116337
[TBL] [Abstract][Full Text] [Related]
28. Nanoparticle crossing of blood-brain barrier: a road to new therapeutic approaches to central nervous system diseases.
Ceña V; Játiva P
Nanomedicine (Lond); 2018 Jul; 13(13):1513-1516. PubMed ID: 29998779
[No Abstract] [Full Text] [Related]
29. Transferrin Receptor-Targeted PEG-PLA Polymeric Micelles for Chemotherapy Against Glioblastoma Multiforme.
Sun P; Xiao Y; Di Q; Ma W; Ma X; Wang Q; Chen W
Int J Nanomedicine; 2020; 15():6673-6688. PubMed ID: 32982226
[TBL] [Abstract][Full Text] [Related]
30. Transcytosis of protein through the mammalian cerebral epithelium and endothelium. III. Receptor-mediated transcytosis through the blood-brain barrier of blood-borne transferrin and antibody against the transferrin receptor.
Broadwell RD; Baker-Cairns BJ; Friden PM; Oliver C; Villegas JC
Exp Neurol; 1996 Nov; 142(1):47-65. PubMed ID: 8912898
[TBL] [Abstract][Full Text] [Related]
31. Current approaches for drug delivery to central nervous system.
Hossain S; Akaike T; Chowdhury EH
Curr Drug Deliv; 2010 Dec; 7(5):389-97. PubMed ID: 20950269
[TBL] [Abstract][Full Text] [Related]
32. Targeting central nervous system pathologies with nanomedicines.
Mizrahy S; Gutkin A; Decuzzi P; Peer D
J Drug Target; 2019; 27(5-6):542-554. PubMed ID: 30296187
[TBL] [Abstract][Full Text] [Related]
33. Drug delivery across the blood-brain barrier: recent advances in the use of nanocarriers.
Mulvihill JJ; Cunnane EM; Ross AM; Duskey JT; Tosi G; Grabrucker AM
Nanomedicine (Lond); 2020 Jan; 15(2):205-214. PubMed ID: 31916480
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates.
Yu YJ; Atwal JK; Zhang Y; Tong RK; Wildsmith KR; Tan C; Bien-Ly N; Hersom M; Maloney JA; Meilandt WJ; Bumbaca D; Gadkar K; Hoyte K; Luk W; Lu Y; Ernst JA; Scearce-Levie K; Couch JA; Dennis MS; Watts RJ
Sci Transl Med; 2014 Nov; 6(261):261ra154. PubMed ID: 25378646
[TBL] [Abstract][Full Text] [Related]
35. Two peptides targeting endothelial receptors are internalized into murine brain endothelial cells.
Hudecz D; Sigurdardóttir SB; Christensen SC; Hempel C; Urquhart AJ; Andresen TL; Nielsen MS
PLoS One; 2021; 16(4):e0249686. PubMed ID: 33798235
[TBL] [Abstract][Full Text] [Related]
36. CNS drug delivery systems: novel approaches.
Pathan SA; Iqbal Z; Zaidi SM; Talegaonkar S; Vohra D; Jain GK; Azeem A; Jain N; Lalani JR; Khar RK; Ahmad FJ
Recent Pat Drug Deliv Formul; 2009 Jan; 3(1):71-89. PubMed ID: 19149731
[TBL] [Abstract][Full Text] [Related]
37. Blood-brain barrier transport using a high affinity, brain-selective VNAR antibody targeting transferrin receptor 1.
Stocki P; Szary J; Rasmussen CLM; Demydchuk M; Northall L; Logan DB; Gauhar A; Thei L; Moos T; Walsh FS; Rutkowski JL
FASEB J; 2021 Feb; 35(2):e21172. PubMed ID: 33241587
[TBL] [Abstract][Full Text] [Related]
38. Blood-Brain Barrier Transport, Plasma Pharmacokinetics, and Neuropathology Following Chronic Treatment of the Rhesus Monkey with a Brain Penetrating Humanized Monoclonal Antibody Against the Human Transferrin Receptor.
Pardridge WM; Boado RJ; Patrick DJ; Ka-Wai Hui E; Lu JZ
Mol Pharm; 2018 Nov; 15(11):5207-5216. PubMed ID: 30226787
[TBL] [Abstract][Full Text] [Related]
39. Selective drug delivery approaches to lesioned brain through blood brain barrier disruption.
Al-Ahmady ZS
Expert Opin Drug Deliv; 2018 Apr; 15(4):335-349. PubMed ID: 29466890
[TBL] [Abstract][Full Text] [Related]
40. Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?
Sanchez-Covarrubias L; Slosky LM; Thompson BJ; Davis TP; Ronaldson PT
Curr Pharm Des; 2014; 20(10):1422-49. PubMed ID: 23789948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
